Mast To Develop Vepoloxamer (MST-188) In Chronic Heart Failure
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- Wall St slips as Middle East escalations lifts oil; Trump-Xi talks in focus
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Plug Power COO resigns to join another company
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- Wall Street ends down as oil prices, Treasury yields rise
Mast Therapeutics (MSTX) to Develop Vepoloxamer (MST-188) to Treat Chronic Heart Failure
March 23, 2015 8:03 AM EDTMast Therapeutics (NYSE: MSTX) today announced its plans to develop vepoloxamer (MST-188) for the treatment of patients with chronic heart failure. Encouraged by recently reported nonclinical results and input from experts in the field, the Company expects to begin dosing in a Phase 2 study of vepoloxamer in patients with chronic heart failure in the third quarter of this year.
Wilson S. Colucci M.D., Professor of Medicine and Physiology and Chief of Cardiovascular Medicine at Boston University School of Medicine said: "The results from studies in experimental heart failure are encouraging and support... More
